Commodore Capital LP Increases Stake in EyePoint, Inc. to 5.1%

On June 3, 2026, Commodore Capital LP and its affiliates filed a Schedule 13G with the SEC, reporting a significant increase in their stake in EyePoint, Inc. (EYPT). As of the event date on May 27, 2026, the filers—including Commodore Capital Master LP and managing partners Robert Egen Atkinson and Michael Kramarz—beneficially own 4,250,000 shares of Common Stock. This position represents approximately 5.1% of the company's 83,841,298 outstanding shares. This filing marks an increase from their previously reported position of 2,825,000 shares. Commodore Capital LP serves as the investment manager to Commodore Capital Master LP, with Atkinson and Kramarz exercising shared voting and dispositive power over the securities. The filing was made under Rule 13d-1(c), indicating a passive investment intent, and includes a joint filing agreement between the reporting persons. The reported value of the holdings is approximately $52,445,000 based on the current share count. EyePoint, Inc. is a Watertown-based pharmaceutical company focused on ophthalmic treatments.